Loading clinical trials...

Growth and Asymmetric diMethylArginine | Clinical Trials | Clareo Health

COMPLETED

Growth and Asymmetric diMethylArginine

Validation of the Dosage of Asymmetric Dimethylarginine (ADMA) Plasma in the Assessment of Endothelial Dysfunction During Growth Hormone Deficiency and Intrauterine Growth Retardation

NCT03422081•University Hospital, Lille

View on ClinicalTrials.gov

Summary

Principal objective : Validation of a handy biochemical parameter, plasma concentration of Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation of the brachial artery, at ultrasound examination, after the deflation of a cushion to evaluate artery dysfunction (vascular suffering) in growth diseases, growth hormone deficiency (GHD) and intrauterine growth retardation (IUGR) Secondary objectives: * Comparison of ADMA plasma concentrations with dose of matched healthy control children * Investigation of the mechanisms of arterial dysfunction, inflammation, oxidative stress and insulin resistance.

Eligibility

Age

3 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Group A: GHD, defined by 2 GH peaks less than 6.6 ng/ml (20 mU/L) at two stimulation tests
•Group B: IUGR, defined by a birth length and/or a birth weight inferior to - 2 SD for gestational age according to Usher and McLean charts
•Group C: Control children matched to children matched to subjects of groups A and B, according to gender and age
•Informed consent signed by representative of the parental authority

Exclusion Criteria

•Chronic disabling disease (ex: diabetes, severe asthma)
•Evolving cancer
•Severe psychiatric disorder (ex: autism, schizophrenia; severe depression)
•Hypothalamic tumor (ex: craniopharyngioma)
•Anamnesis of cranial irradiation
•Overweight, obesity or thinness
•Precocious puberty
•Non-replacing therapy by glucocorticoids or sex steroids less than 1 month before the exploration
•Anterior treatment by recombinant human GH
•Other conditions, treatments or habits impacting arterial reactivity: acrocyanosis, cryoglobulinemia, beta adrenergic blocking habits, tobacco smoking or other drug addictions, dyslipidemia
+5 more criteria

Locations (2)

Hôpital Jeanne de Flandre - CHRU de Lille

Lille, France

CHU Purpan

Toulouse, France

Key Dates

Start Date

June 1, 2014

Primary Completion Date

December 31, 2018

Completion Date

December 31, 2018

Last Updated

December 16, 2025

Enrollment

ACTUAL participants

Conditions

Growth Hormone DeficiencySmall-for-gestational Age

Interventions

arterial doppler ultrasound

DIAGNOSTIC_TEST

Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired Growth Hormone Deficiency.

NCT07333521

Isolated Non-acquired Growth Hormone Deficiency

View study

RECRUITING

Chromosome 18 Clinical Research Center

NCT00227253

Chromosome AberrationsGrowth Hormone Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Growth and Asymmetric diMethylArginine

Inclusion Criteria

Exclusion Criteria

Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired Growth Hormone Deficiency.

Chromosome 18 Clinical Research Center

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.